HC Wainwright Has Optimistic Outlook of ANIX Q3 Earnings

Anixa Biosciences Inc (NASDAQ:ANIX) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Anixa Biosciences in a research note issued to investors on Thursday, June 11th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.31) EPS.

Several other equities analysts have also recently commented on ANIX. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, April 8th. Finally, Wall Street Zen downgraded Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $2.47 on Monday. Anixa Biosciences has a 52-week low of $2.32 and a 52-week high of $5.46. The company has a market capitalization of $84.03 million, a PE ratio of -7.97 and a beta of 0.59. The business’s fifty day moving average is $2.78 and its 200 day moving average is $3.09.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new position in Anixa Biosciences in the fourth quarter worth $355,000. ExodusPoint Capital Management LP bought a new position in Anixa Biosciences in the fourth quarter valued at $293,000. Susquehanna International Group LLP raised its position in Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after purchasing an additional 63,584 shares in the last quarter. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the fourth quarter valued at about $161,000. Finally, State Street Corp lifted its stake in Anixa Biosciences by 32.0% during the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares during the last quarter. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.